Cytoskeletal myotoxicity from simvastatin and colchicine

Muscle and Nerve

Volumn 30, Issue 6, 2004, Pages 799-802

  Baker, Steven K ^a   Goodwin, Susan ^b   Sur, Monalisa ^c   Tarnopolsky, Mark A ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Colchicine; Cytoskeleton; Myotoxicity; Rhabdomyolysis; Statin

Indexed keywords

AMPICILLIN; COLCHICINE; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPRENOID; SIMVASTATIN;

AGED; ARTICLE; CASE REPORT; CELL FUNCTION; CELL VACUOLE; CHRONIC KIDNEY FAILURE; CYTOSKELETON; CYTOTOXICITY; DRUG EXPOSURE; DRUG METABOLISM; GOUT; HOSPITAL INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MICROTUBULE; MUSCLE DISEASE; MUSCLE NECROSIS; MYOPATHY; PRENYLATION; PRIORITY JOURNAL; RHABDOMYOLYSIS;

AGED; COLCHICINE; CYTOSKELETON; HUMANS; MALE; MUSCULAR DISEASES; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 10044225589     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.20135     Document Type: Article

References (15)

1. Anderson PJ, Song SK, Slotwiner P. The fine structure of spheromembranous degeneration of skeletal muscle induced by vincristine. J Neuropathol Exp Neurol 1967;26:15-24.
2. Bifulco M, Laezza C, Aloj SM, Garbi C. Mevalonate controls the cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 1993;155:340-348.
3. Boudriau S, Vincent M, Cote CH, Rogers PA. Cytoskeletal structure of skeletal muscle: identification of an intricate exosarcomeric microtubule lattice in slow- and fast-twitch muscle fibers. J Histochem Cytochem 1993;41:1013-1021.
4. Carr AA. Colchicine toxicity. Arch Intern Med 1965;115:29-33.
5. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000;16:89-111.
6. Essig M, Vrtovsnik F, Friedlander G. Inhibitors of HMG-CoA reductase: new modes of action, new indications. Therapie 2000;55:43-49.
7. Fernandez C, Figarella-Branger D, Alla P, Harle J-R, Pellissier J-F. Colchicine myopathy: a vacuolar myopathy with selective type I muscle fiber involvement. Acta Neuropathol 2002;103:100-106.
8. Flint OP, Masters BA, Gregg RE, Durham SK. HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lova-statin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 1997;145:99-110.
9. Hsu W-C, Chen W-H, Chang M-T, Chiu H-C. Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol 2002;25:266-268.
10. Kontos HA. Myopathy associated with chronic colchicine toxicity. N Engl J Med 1962;166:38-39.
11. Kuncl RW. Chronic human colchicine myopathy and neuropathy. Arch Neurol 1988;45:245-246.
12. Kuncl RW, Bilak MM, Craig SW, Adams R. Exocytotic " constipation" is a mechanism of tubulin/lysosomal interactions in colchicine myopathy. Exp Cell Res 2003;285:196-207.
13. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987;316:1562-1568.
14. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-66.
15. Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. Eur J Neurosci 2003;17:93-102.